The Capacity of the Ovarian Cancer Tumor Microenvironment to Integrate Inflammation Signaling Conveys a Shorter Disease-free Interval
Abstract
Ovarian cancer has one of the highest deaths to incidence ratios across all cancers. Initial chemotherapy is effective, but most patients develop chemoresistant disease. Mechanisms driving clinical chemo-response or -resistance are not well-understood. However, achieving optimal surgical cytoreduction improves survival, and cytoreduction is improved by neoadjuvant chemotherapy (NACT). NACT offers a window to profile pre- versus post-NACT tumors, which we used to identify chemotherapy-induced changes to the tumor microenvironment.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Dec 01, 2020
- Source ID
- 10.1158/1078-0432.ccr-20-1762
Entities
People
- Aaron Clauset
- Angela Minic
- Benjamin G Bitler
- James Costello
- Jennifer K Richer
- Jill E Slansky
- Junxiao Hu
- Kian Behbakht
- Kimberly R Jordan
- Marisa R Moroney
- Matthew J Sikora
- Rebecca J. Wolsky
- T. Rajendra Kumar
- Tomomi M. Yamamoto
- Zachary L Watson
Organizations
- Anschutz Medical Campus
- Colorado Clinical and Translational Sciences Institute
- National Institutes of Health
- The University of Texas MD Anderson Cancer Center
- United States Department of Defense
- University of Colorado
- University of Colorado Cancer Center
- University of Colorado Denver